Insulin glargine improves hemoglobin Alc in children and adolescents with poorly controlled type 1 diabetes

Pediatric Diabetes

Volumn 4, Issue 2, 2003, Pages 64-69

  Jackson, Anne ^a   Ternand, Christine ^a   Brunzell, Carol ^a   Kleinschmidt, Teresa ^a   Dew, Dawn ^a   Milla, Carlos ^a   Moran, Antoinette ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adolescents; Insulin glargine; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ADOLESCENT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC KETOACIDOSIS; DRUG ABSORPTION; DRUG RESPONSE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; JUVENILE DIABETES MELLITUS; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TIME;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE;

EID: 0038726019     PISSN: 1399543X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5448.2003.00014.x     Document Type: Article

References (25)

1. The DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: the DCCT. J Pediatr 1994: 125: 177-188.
2. Rogers DB, White NH, Shalwitz RA et al. The effect of puberty on the development of early diabetic microvascular disease in insulin-dependent diabetes. Diabetes Res Clin Pract 1987: 3: 39-44.
3. Holl RW, Lange GE, Grabert M, Heinze E, Lang GK, Debatin KM. Diabetic retinopathy in pediatric patients with type 1 diabetes. Effect of diabetes duration, prepubertal and pubertal onset of diabetes and metabolic control. J Pediatr 1998: 132: 790-794.
4. Rudberg S, Dahlquist G. Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 1996: 19: 369-371.
5. Lawson M, Sochett EB, Chait PG, Balfe JW, Daneman D. Effect of puberty on markers of glomerular hypertrophy and hypertension in diabetes. Diabetes 1996: 45: 51-55.
6. McNally PG, Raymond NT, Swift PGF, Hearnshaw FR, Burden AC. Does the prepubertal duration of diabetes influence the onset of microvascular complications? Diabet Med 1993: 10: 906-908.
7. Donaghue KC, Fung ATW, Hing S et al.The effect of prepubertal diabetes duration on diabetes. Diabetes Care 1997: 20: 77-80.
8. Schultz CJ, Neil HAW, Dalton RN, Dunger DB. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis of type 1 diabetes. Diabetes Care 2000: 23: 1811-1815.
9. Matyka K, Wigg L, Pramming S, Dunger DB. Cognitive function and mood after profound nocturnal hypoglycemia in prepubertal children with conventional insulin treatment for diabetes. Arch Dis Child 1999: 81: 138-142.
10. Porter PA, Byrne G, Stick S, Jones TW. Nocturnal hypoglycemia and sleep disturbances in young teenagers with insulin dependent diabetes mellitus. Arch Dis Child 1996: 72: 120-123.
11. Ahern JAH, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, Tamborlane WV. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002: 3: 10-15.
12. Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge J, Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000: 23: 557-559.
13. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of infusion lispro. Diabetes 2000: 49: 2142-2148.
14. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125, I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000: 23: 813-819.
15. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Glargine at PSGoI. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 369-376.
16. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K And The Pediatric Study Group Of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes (letter). Diabetes Care 2001: 24: 2005-2006.
17. Dunger DB, Edge JA, Skvor J. Insulin glargine provides long-term effective glycemic control in children and adolescents with type 1 diabetes (abstract). Diabetes 2002: 51(Suppl. 2): 1750-P.
18. Murphy NP, Keane SM, Ong KK, et al. Randomized crossover trial of insulin glargine plus Lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003: 26: 799-804.
19. Kordonouri O, Deiss D, Hopfenmueller W, Leupke K, Von Schuetz W, Danne T. Treatment with insulin glargine reduces asymptomatic nightly hypoglycemia, detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes (Abstract). Diabetes 2002: 51(Suppl. 2): 1754-P.
20. Pieber TR, Eugene-Jolchine I, Derobert E For The European Study Group Of HOE. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000: 23: 157-162.
21. Ratner RE, Hirsch IB, Neifing JL, et al. Study Group of Insulin Glargine in Type 1 Diabetes: less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000: 23: 639-643.
22. Rosenstock J, Park G, Zimmerman J. Group For the U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group: Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000: 23: 1137-1142.
23. Raskin P, Klaff L, Bergenstal R, Halle J, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000: 23: 1666-1671.
24. Yki-Jarvinen H, Dressler A, Ziemen M. The HOE 901/3002 Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000: 23: 1130-1136.
25. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001: 18: 619-625.